April 30, 2016
Recommended Topic Related To:

Incruse Ellipta

"On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need f"...


Incruse Ellipta



No case of overdose has been reported with INCRUSE ELLIPTA.

High doses of umeclidinium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a once-daily inhaled dose of up to 1,000 mcg umeclidinium (16 times the maximum recommended daily dose) for 14 days in subjects with COPD.

Treatment of overdosage consists of discontinuation of INCRUSE ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy.


The use of INCRUSE ELLIPTA is contraindicated in the following conditions:

  • Severe hypersensitivity to milk proteins [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity to umeclidinium or any of the excipients [see WARNINGS AND PRECAUTIONS, DESCRIPTION]
This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 3/7/2016


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.